Westlake Village-based Sienna Biopharmaceuticals reported that operating expenses rose 41 percent for its fourth quarter to $19.8 million, topping $76 million in 2018. The pre-revenue company ended the year with $48.5 million in cash and cash equivalents and raised another $21.3 million in net proceeds from a stock offering in February as it advanced clinical…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
